Formation of a high thrombogenic risk groups in children with manifestation of hemorrhagic syndrome

Introduction. Children suffering from congenital thrombophilia may suffer from manifestations of the increased bleeding in certain periods of childhood. With regard to the occurrence of acute cerebrovascular accident, infarctions, transient ischemic attacks, genetic polymorphisms of thrombophilia have been well studied, but they have not been fully analyzed in children with the aspects of hemorrhagic syndrome. The aim of the study: to assess the prognostic significance of permanent and temporary thrombogenic risk factors for the formation of a risk groups for the development of vascular complications in children with manifestations of hemorrhagic syndrome.

Materials and methods. The study included ninety 0 to 18 years children with clinical manifestations of hemorrhagic syndrome. The control group consisted of 115 children without clinical manifestations of bleeding. Determination of genetic polymorphisms of hemostasis system factors and folate cycle enzymes was carried out by the molecular genetic method, using the polymerase chain reaction. Statistical processing of the results was carried out using the statistical software package Statistica 10.0 (StatSoft Inc.) was used to organize, sort, and analyze data.

Results. Children with manifestation of hemorrhagic syndrome were established to have a statistically significant prevalence of carriage of the Hmzg genotype of the ITGA2 gene and the Hmzg gene PAI-1 (p < 0.05). The prognostic significance and informativeness of a number of constant and temporary signs were established, from which a prognostic table was compiled for the selection of children in the risk group for the development of vascular complications with the subsequent development of individual measures for primary thromboprophylaxis.

Conclusion. Thus, the developed prognostic table characterizes the maximum value of specificity, the maximum value of sensitivity and the prognostic randomness of a positive result. When working with the proposed table, no more than 5% of erroneous decisions can be made. Using this indicator, children with a risk of developing vascular diseases were identified and included in the regional register, with subsequent additional examination and specific thromboprophylaxis.

Contribution:
Strozenko L.A. — concept, research design;
Ponomarev V.S. — collection and processing of material, writing the text;
Lobanov Yu.F., Skudarnov E.V. — editing the text.
All co-authors — approval of the final version of the article, responsibility for the integrity of all parts of the article.

Acknowledgment. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: July 10, 2024
Accepted: August 07, 2024
Published: September 16, 2024

1. Mahajerin A., Croteau S.E. Epidemiology and risk assessment of pediatric venous thromboembolism. Front. Pediatr. 2017; 5: 68. https://doi.org/10.3389/fped.2017.00068

2. Male C., Ay C., Crevenna R., Eichinger S., Feistritzer C., Füller R., et al. Treatment of haemophilia in Austria. Wien. Klin. Wochenschr. 2024; 136(Suppl. 4): 75–102. https://doi.org/10.1007/s00508-024-02370-0 (in German)

3. Windyga J., Boban A., Zupan I., O’Connell N., Hermans C. Changing paradigms of hemophilia care across larger specialized treatment centers in the European region. Ther. Adv. Hematol. 2022; 13: 20406207221088462. https://doi.org/10.1177/20406207221088462

4. Noone D., O’Mahony B., Peyvandi F., Makris M., Bok A. Evolution of haemophilia care in Europe: 10 years of the principles of care. Orphanet. J. Rare Dis. 2020; 15(1): 184. https://doi.org/10.1186/s13023-020-01456-y

5. Abbate R., Sofi F., Gensini F., Fatini C., Sticchi E., Fedi S. Thrombophilias as risk factors for disorders of pregnancy and fetal damage. Pathophysiol. Haemost. Thromb. 2002; 32(5-6): 318–21. https://doi.org/10.1159/000073589

6. Baldwin M.K., Samuelson Bannow B., Rosovsky R.P., Sokkary N., Srivaths L.V. Hormonal therapies in females with blood disorders: thrombophilia, thrombosis, hemoglobinopathies, and anemias. Res. Pract. Thromb. Haemost. 2023; 7(4): 100161. https://doi.org/10.1016/j.rpth.2023.100161

7. Hart C., Wohlfarth O., Heimerl S. Bleeding diathesis in the general practice: diagnostic approach and treatment. MMW Fortschr. Med. 2018; 160(6): 50–8. https://doi.org/10.1007/s15006-018-0012-4 (in German)

8. Komarova A.D. Rare cases of diagnosis of late hemorrhagic disease in children with progressive familial intrahepatic cholestasis type 2. Rossiyskiy pediatricheskiy zhurnal. 2020; 23(6): 402. https://elibrary.ru/ndveex (in Russian)

9. Zöller B., García de Frutos P., Hillarp A., Dahlbäck B. Thrombophilia as a multigenic disease. Haematologica. 1999; 84(1): 59–70.

10. Nartikoeva M.I. The role of gene polymorphism in the cardiovascular system diseasestreatment. Sovremennye problemy nauki i obrazovaniya. 2020; (6): 204. https://doi.org/10.17513/spno.30436 https://elibrary.ru/tuagky (in Russian)

11. Pschenichnaya K.I. Hemorrhagic syndrome in children and adolescents with markers of hereditary thrombophilia. Pediatriya. Zhurnal imeni G.N. Speranskogo. 2009; 87(4): 64–7. https://elibrary.ru/kvjwmf (in Russian)

12. Arachchillage D.J., Mackillop L., Chandratheva A., Motawani J., MacCallum P., Laffan M. Thrombophilia testing: A British Society for Haematology guideline. Br. J. Haematol. 2022; 198(3): 443–58. https://doi.org/10.1111/bjh.18239

13. Strozenko L.A., Skudarnov E.V., Lobanov Yu.F., Vyhodtseva G.I., Dorokhov N.A., Zenchenko O.A., et al. Distribution of prothrombotic polymorphisms in children with microcirculatory type of bleeding on the background of undifferentiated connective tissue dysplasia. Rossiyskiy Pediatricheskiy Zhurnal. 2020; 23(2): 85–94. https://doi.org/10.18821/1560-9561-2020-23-2-85-94 https://elibrary.ru/hybtlh (in Russian)

14. Andrade J.V., Magalhães J., Resende C., Gomes D., Laranjo G., Campos J., et al. Venous thromboembolism in pediatric age: a 15-year retrospective review. Acta Med. Port. 2018; 31(9): 489–95. Portuguese. https://doi.org/10.20344/amp.9639

15. Alqahtani S., Gibbs K.D., Montanez N.A., Krause K.J., van Ommen C.H., Srivaths L.V. Direct oral anticoagulant therapy in adolescent venous thromboembolism: A systematic review. Pediatr. Blood Cancer. 2024; 71(9): e31131. https://doi.org/10.1002/pbc.31131

16. AbdelAziz N.H., AbdelAzeem H.G., Monazea E.M., Sherif T. Impact of thrombophilia on the risk of hypoxic-ischemic encephalopathy in term neonates. Clin. Appl. Thromb. Hemost. 2017; 23(3): 266–73. https://doi.org/10.1177/1076029615607302

17. Abbattista M., Capecchi M., Martinelli I. Treatment of unusual thrombotic manifestations. Blood. 2020; 135(5): 326–34. https://doi.org/10.1182/blood.2019000918

18. Aborkhees G., Mitchell L.G. Predicting risk for recurrence of arterial ischemic stroke in children: thrombophilia as another piece of the puzzle. Haematologica. 2019; 104(8): 1513–4. https://doi.org/10.3324/haematol.2019.222695

19. Andrew M., Michelson A.D., Bovill T., Leaker M., Massicotte P., Marzinotto V., et al. The prevention and treatment of thromboembolic disease in children: a need for Thrombophilia Programs. J. Pediatr. Hematol. Oncol. 1997; 19(1): 7–22. https://doi.org/10.1097/00043426-199701000-00002

20. Surkova E.V., Antsiferov M.B., Fletcher R., Fletcher S., Wagner E. Clinical Epidemiology. The Basics of Evidence-Based Medicine [Klinicheskaya epidemiologiya. Osnovy dokazatel’noy meditsiny]. Moscow: Media Sfera; 1998. (in Russian)

21. Wald A. Sequential Analysis. John Wiley; 1947.

22. Kullbak S. Information Theory and Statistics. New York, London: John Wiley & Sons, Chapman & Hall; 1959.

23. Strozenko L.A., Lobanov Yu.F., Kolesnikova M.A., Rychkova O.A., Tsyvkina L.P., Momot A.P. Risk factors in children with acute cerebral circulation disorders by ischemic type. Pediatriya. Zhurnal im. G.N. Speranskogo. 2020; 99(2): 163–72. https://doi.org/10.24110/0031-403X-2020-99-2-163-172 https://elibrary.ru/brzgoe (in Russian)

24. Ponomarev V.S., Skudarnov E.V., Strozenko L.A., Dorokhov N.A., Malyuga O.M., Zenchenko O.A. Screening of thrombogenic risk factors in children in the Altai Krai. Rossiyskiy Pediatricheskiy Zhurnal. 2023; 26(1): 61–6. https://doi.org/10.46563/1560-9561-2023-26-1-61-66 https://elibrary.ru/fdyygi (in Russian)

25. Strozenko L.A., Gordeev V.V., Lobanov Yu.F., Ryabinina E.A., Momot A.P., Tsyvkina L.P., et al. Methodology for creating of adolescents group with high thrombogenic risk in Altai region. Thromboz, hemostaz i rheologiya. 2013; (4): 45–50. https://elibrary.ru/rinzgz (in Russian)

26. Sanchez A., Campanella L., Perez K. Optimization of thromboprophylaxis use in hospitalized pediatric patients through implementation of a venous thromboembolism risk assessment tool. J. Pediatr. Pharmacol. Ther. 2023; 28(5): 452–6. https://doi.org/10.5863/1551-6776-28.5.452

27. Abrams C.M., Jaffray J., Stillings A., Branchford B.R., Young G., Goldenberg N.A., et al. Current practices in pediatric hospital-acquired thromboembolism: Survey of the Children’s Hospital Acquired Thrombosis (CHAT) Consortium. Res. Pract. Thromb. Haemost. 2022; 6(7): e12793. https://doi.org/10.1002/rth2.12793

28. Walker S.C., French B., Moore R.P., Domenico H.J., Wanderer J.P., Mixon A.S., et al. Model-guided decision-making for thromboprophylaxis and hospital-acquired thromboembolic events among hospitalized children and adolescents: The CLOT randomized clinical trial. JAMA Netw. Open. 2023; 6(10): e2337789. https://doi.org/10.1001/jamanetworkopen.2023.37789